HLB bioStep Co.,Ltd. (KOSDAQ:278650)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,360.00
-125.00 (-1.93%)
At close: Apr 23, 2026
Market Cap107.65B -28.2%
Revenue (ttm)74.05B +27.3%
Net Income-18.96B
EPS-1,120.00
Shares Out16.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume122,193
Average Volume74,551
Open6,505.00
Previous Close6,485.00
Day's Range6,220.00 - 6,505.00
52-Week Range5,430.00 - 10,100.00
Beta-0.04
RSI46.83
Earnings DateNov 14, 2025

About HLB bioStep

HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug development consulting and clinical trial services, and bioanalysis items. The company was formerly known as KNOTUS Co.,Ltd. HLB bioStep Co.,Ltd. was found... [Read more]

Industry Commercial Physical and Biological Research
Founded 2012
Employees 147
Stock Exchange KOSDAQ
Ticker Symbol 278650
Full Company Profile

Financial Performance

In 2025, HLB bioStep's revenue was 74.05 billion, an increase of 27.30% compared to the previous year's 58.17 billion. Losses were -18.96 billion, 121.4% more than in 2024.

Financial Statements